The Major Cat Allergen, Fel d 1, in Diagnosis and Therapy
Open Access
- 22 October 2009
- journal article
- review article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 151 (4), 265-274
- https://doi.org/10.1159/000250435
Abstract
Sensitization to cat is a common cause of allergic disease all over the world. Symptoms range from mild rhinoconjunctivitis to potentially life-threatening asthmatic exacerbations. In vivo and in vitro diagnostics of cat allergy is currently based on cat dander extract. As allergen extracts from natural sources are heterogeneous in composition, the allergen content may vary. With the introduction of allergens produced by recombinant techniques, a large panel of recombinant allergenic molecules including the major cat allergen, recombinant Fel d 1, has become available for immunological investigations, diagnosis and treatment. Studies have shown that this single allergen, which belongs to the uteroglobin protein family, is at least as good as cat dander extract in identifying cat-allergic patients. The introduction of recombinant Fel d 1-based tests into clinical practice will increase our knowledge of this single allergen molecule as a diagnostic tool and improve the selection for therapy of cat allergy. Several different modes for allergen-specific immunotherapy of cat allergy based on Fel d 1 have been developed. These include Fel d 1 hypoallergens and allergen constructs where Fel d 1 is coupled to immunomodulatory proteins or carriers. The approaches have been evaluated in experimental in vitro and in vivo model systems with promising results. In addition, immunotherapy with Fel d 1 peptides containing T-cell epitopes has been tested in clinical trials. After initial problems with adverse reactions, more recent data show that peptide immunotherapy modulates the immune response to Fel d 1 and reduces early- and late-phase effector reactions in cat-allergic patients.Keywords
This publication has 29 references indexed in Scilit:
- Prolonged antigen‐exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized miceAllergy, 2009
- Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopesClinical & Experimental Allergy, 2008
- “Accentuate the negative, eliminate the positive”: Engineering allergy therapeutics to block allergic reactivity through negative signalingJournal of Allergy and Clinical Immunology, 2008
- Structural Characterization of the Tetrameric form of the Major Cat Allergen Fel d 1Journal of Molecular Biology, 2007
- A chimeric human-cat Fcγ-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergenClinical Immunology, 2006
- Peptide therapy for allergic diseases: Basic mechanisms and new clinical approachesPharmacology & Therapeutics, 2005
- Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjectsClinical & Experimental Allergy, 2005
- Fel d 4, a cat lipocalin allergenClinical & Experimental Allergy, 2004
- Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in Escherichia coliOnline Journal of Public Health Informatics, 2003
- The Crystal Structure of the Major Cat Allergen Fel d 1, a Member of the Secretoglobin FamilyOnline Journal of Public Health Informatics, 2003